Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

BACKGROUND: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen for treatment of HIV-1 infection. The efficacy/safety of switching to D/C/F/TAF versus continuing boosted protease inhibitor (bPI) + emtricitabine/tenofovir disop...

Descripción completa

Detalles Bibliográficos
Autores principales: Huhn, Gregory D., Eron, Joseph J., Girard, Pierre-Marie, Orkin, Chloe, Molina, Jean-Michel, DeJesus, Edwin, Petrovic, Romana, Luo, Donghan, Van Landuyt, Erika, Lathouwers, Erkki, Nettles, Richard E., Brown, Kimberley, Wong, Eric Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716878/
https://www.ncbi.nlm.nih.gov/pubmed/31464642
http://dx.doi.org/10.1186/s12981-019-0235-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716878/
https://www.ncbi.nlm.nih.gov/pubmed/31464642
http://dx.doi.org/10.1186/s12981-019-0235-1

Ejemplares similares